Cullinan Oncology to Participate in Upcoming Investor Conferences
November 01 2022 - 7:00AM
Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a
biopharmaceutical company focused on modality-agnostic targeted
oncology for patients with cancer, today announced that its
management team will participate in the following investor
conferences.
- Chief Financial Officer Jeff Trigilio will deliver a Company
presentation at the Credit Suisse 31st Annual Healthcare Conference
in Rancho Palos Verdes, CA, on November 8, 2022 at 11:35 a.m.
EST
- Chief Executive Officer Nadim Ahmed will deliver a Company
presentation at the Stifel 2022 Healthcare Conference in New York
on November 16, 2022 at 4:45 p.m. EST
- Mr. Ahmed will participate in a fireside chat at the Evercore
ISI 5th Annual HEALTHCONx conference, being held virtually, on
December 1, 2022 at 8:25 a.m. EST
A live webcast of each event will be available via the Events
section of the Company’s investor relations website at
https://investors.cullinanoncology.com/news-events/events.
Investors interested in scheduling a one-on-one meeting with
Cullinan Oncology’s management should contact their Credit Suisse,
Stifel or Evercore ISI representative.
About Cullinan Oncology Cullinan Oncology, Inc.
(Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating
new standards of care for patients with cancer. We innovate without
borders to find the most promising clinic-ready cancer therapies,
whether from our own discovery efforts or through exceptional
engagement with our academic and industry partners. Anchored in a
deep understanding of immuno-oncology and translational cancer
medicine, we leverage our scientific excellence in small molecules
and biologics to create differentiated ideas, identify unique
targets, and select the optimal modality to develop transformative
therapeutics across cancer indications. Powered by our novel
research model, we push conventional boundaries from candidate
selection to cancer therapeutic, applying rigorous early
experimentation to fast-track only the most promising assets to the
clinic and ultimately commercialization. As a result, our
diversified pipeline is strategically built with assets that
activate the immune system or inhibit key oncogenic drivers across
a wide range of modalities, each with the potential to be the best
or first in their class.
Our people possess deep scientific expertise, seek innovation
openly, and exercise creativity and urgency to deliver on our
promise to bring new therapeutic solutions to patients with cancer.
Learn more about our Company at www.cullinanoncology.com, and
follow us on LinkedIn and Twitter.
Contacts: Investor Relations Chad Messer+1
203.464.8900cmesser@cullinanoncology.com
MediaRose Weldon+1 215.801.7644rweldon@cullinanoncology.com
Cullinan Therapeutics (NASDAQ:CGEM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cullinan Therapeutics (NASDAQ:CGEM)
Historical Stock Chart
From Jul 2023 to Jul 2024